Related Experiment Video

Updated: Oct 4, 2026

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

Prophylactic surgery in patients with inherited risk of ovarian cancer

P Morice, P Pautier, S Delaloge

    Gynecologic Oncology
    |October 19, 2001
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation
    05:42

    Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation

    Published on: October 25, 2024

    Related Experiment Videos

    Last Updated: Oct 4, 2026

    In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
    13:04

    In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

    Published on: October 14, 2015

    Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation
    05:42

    Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation

    Published on: October 25, 2024

    Related Concept Videos

    Oogenesis02:07

    Oogenesis

    In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...

    Articles linked to this work by shared authors, journal, and citation graph.

    Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success.

    ESMO open·2026

    Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.

    Breast (Edinburgh, Scotland)·2026

    Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

    British journal of cancer·2026

    ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    A second chance? Outcomes of immunotherapy retreatment after prior checkpoint inhibitor exposure in endometrial and cervical cancer.

    Gynecologic oncology·2026

    Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States.

    Gynecologic oncology·2026

    Platinum resistant ovarian cancer - No longer a graveyard for drug development.

    Gynecologic oncology·2026

    Molecular biomarkers in uterine sarcomas: a review of reviews with genomic data integration.

    Gynecologic oncology·2026

    Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study.

    Gynecologic oncology·2026

    Prevalence of pathogenic germline variants and indications for testing in a diverse community-based endometrial cancer cohort.

    Gynecologic oncology·2026

    Case report of sequential, bilateral, robotic-assisted lung resections for severe bronchiectasis.

    AME case reports·2026

    A hypoxia-responsive calixarene supramolecular system enables redox-regulated matrix remodeling for postmenopausal osteoporosis.

    Materials today. Bio·2026

    Calcimimetic therapy modified the radiological, surgical, and histopathological features of a parathyroid adenoma.

    JCEM case reports·2026

    FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort.

    Frontiers in immunology·2026

    Correction: The intratumoral microbiome in colorectal cancer: origins, microenvironmental interactions, and new horizons in precision medicine.

    Frontiers in immunology·2026

    Reconstruction of the inferior vena cava using the right ovarian vein following resection of renal cell carcinoma with tumor thrombus directly infiltrating the inferior vena cava: a case report.

    AME case reports·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us